कंपनी का अवलोकन
PRF Technologies Ltd. operates as a clinical stage specialty pharmaceutical entity primarily focused on the reformulation of established therapeutics and delivering extended post-surgical pain relief solutions within the Israeli market. The company develops specific formulations such as PRF-110, a viscous clear oil-based solution designed for direct instillation into surgical sites to manage pain. This firm functions within the broader Healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on niche medical treatments rather than mass-market consumer goods. The company's market capitalization stands at $1.98M, while its trailing twelve-month revenue is recorded at $17,000, with no employee count data available in the provided records. These financial figures indicate that the organization is a micro-cap entity operating on a very small scale, suggesting limited operational footprint and a high degree of sensitivity to minor shifts in clinical trial outcomes or regulatory approvals.
वित्तीय स्वास्थ्य
The company reported a revenue of $17,000 over the trailing twelve months, yet it recorded a net income of $-4,838,000 and an EBITDA of $-4,348,000, revealing a significant disparity between top-line sales and bottom-line profitability. This substantial gap between the minimal revenue and the large negative net income highlights an extremely fragile cost structure where expenses, likely driven by research and development or clinical trial costs, vastly exceed current sales generation. The free cash flow stands at $-2,002,250, which indicates that the company is currently burning cash rapidly and lacks immediate financial flexibility to fund operations without external capital injection. Regarding profitability metrics, the gross margin is 0.0%, the operating margin is -16200.0%, and the profit margin is 0.0%, each figure pointing to a business model that has not yet achieved operational efficiency or cost coverage at the current scale. The balance sheet shows cash reserves of $4.14M against a negligible debt level of $21,000, resulting in a debt-to-equity ratio of 0.23, which suggests the company is currently unleveraged and not utilizing debt financing. Furthermore, the current ratio is 1.78, indicating that the company possesses 1.78 units of current assets for every unit of current liabilities, reflecting a conservative stance on short-term liquidity management despite the cash burn. Finally, the return on equity is -90.4% and the return on assets is -38.7%, metrics that reveal management has not yet generated positive returns on the capital base deployed in the business.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is listed as N/A due to losses, while the forward P/E is -0.19, a negative figure that implies earnings are expected to remain negative or that the forward estimate relies on non-GAAP adjustments that do not reflect current profitability. The price-to-book ratio stands at 0.23, indicating that the market values the company at a significant discount to its net asset value, suggesting investors are pricing in substantial risks or potential liquidation scenarios rather than a market premium. The price-to-sales ratio is exceptionally high at 116.25, and the EV/EBITDA is 0.32, which suggests that traditional valuation multiples are not applicable and that the market is relying on asset-based or revenue-based metrics to assess value given the lack of earnings. The stock's 52-week high was $17.95 and the 52-week low was $1.80, meaning the current share price is trading at a significant discount relative to the recent high, reflecting the high volatility associated with pre-revenue biotech stocks. The beta is 0.71, which indicates that the stock price is less volatile than the broader market, moving with 71% of the intensity of the overall market index during periods of fluctuation.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that there is insufficient historical data to calculate a growth rate or compare performance against the prior year. In the absence of positive earnings, the concept of a sustainable payout ratio does not apply to this company, as it is unable to distribute dividends to shareholders. Consequently, the company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests any available capital or relies on external funding to finance its growth initiatives rather than returning cash to investors. The overall growth and income profile for PRF Technologies Ltd. is characterized by a complete absence of current profitability, dividend income, or calculable historical growth rates, relying entirely on future clinical developments and potential regulatory milestones to generate value for its shareholders.